PASG Passage Bio Inc.

12.53
-1.1  -8%
Previous Close 13.63
Open 13.63
Price To Book 3.29
Market Cap 573,852,636
Shares 45,798,295
Volume 76,556
Short Ratio
Av. Daily Volume 0
Stock charts supplied by TradingView

NewsSee all news

  1. Passage Bio to Participate in Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day

    PHILADELPHIA, March 27, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1/2 trial to be initiated 1H 2020.
PBGM01
GM1 gangliosidosis
Phase 1/2 trial to be initiated 2H 2020.
PBFT02
Frontotemporal dementia
Phase 1/2 trial to be initiated 1H 2021.
PBFT02
Krabbe disease

Latest News

  1. Passage Bio to Participate in Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day

    PHILADELPHIA, March 27, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today